Vaccine to prevent HPV-related cancers
Part of Cancer, Infections clinical trials.
This trial tests a new vaccine called RG1-VLP that may help prevent cancers caused by HPV. It is for healthy women who have not had an HPV vaccine before and are willing to follow study procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 60 years old.
- You have not had any HPV vaccine, like Gardasil or Cervarix.
- You have never had genital warts or treatment for abnormal cells in the cervix, anus, vagina, or vulva.
- Your blood counts and organ function are within normal limits (checked by blood tests).
- You are HIV, hepatitis B, and hepatitis C negative.
- You are not pregnant, not breastfeeding, and agree to use birth control during the trial (if of childbearing age).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental vaccine (RG002) for women with cervical pre-cancer caused by HPV types 16 or 18. The vaccine is designed to help the body fight the virus and potentially clear the pre-cancerous cells, possibly avoiding more invasive treatments.
This trial tests two experimental vaccines to boost the immune system against HPV 16. Healthy relatives of patients with HPV 16 cancer receive the vaccines, then donate blood cells for research.
This trial tests an experimental vaccine for women who have HPV type 16 but only mild or no precancerous changes (CIN1 or less). The vaccine uses a special device to help your body's immune system fight the virus, which may prevent it from becoming cervical cancer.
This trial tests a new vaccine (pBI-11) given with a device that uses mild electric pulses to help the vaccine enter cells. It is for people who have HPV16 or 18 but no high-grade cervical changes.
This Phase 1 study tests FluBHPVE6E7, a new treatment designed to help the immune system respond to HPV16. It mainly checks safety and the best dose, and may help your body clear or control HPV over time.
This early-phase study tests a vaccine designed to help your immune system fight HPV16, a type of human papillomavirus linked to abnormal cells in the cervix. You may or may not be living with HIV, and the team will check safety and immune response after giving the vaccine in a specific way.
Hear when a new Human Papillomavirus-Related Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.